British Biotech Pharmaceuticals Limited

British Bio-technology Limited

Keith Martyn Dawson

Michael George Hunter

Richard Mark Edwards

Richard James Gilbert

Lars Michael Wood

Lloyd George Czaplewski

Michael Berisford Comer

Joan M Forman

Anthony Fallon

Stewart Craig

Lloyd G Czaplewski

This invention relates to mutants of human RANTES (hRANTES) which, relative to the wild-type molecule, have a reduced tendency to aggregate into large multimeric complexes at physiological ionic strength and pH, and are less pro-inflammatory.

Disaggregated mutant human RANTES

Plasmin precursors are modified so that they exhibit resistance to inhibitors of plasmin. These modified plasmin precursors have fibrinolytic, thrombolytic or antithrombotic properties, which are useful in the treatment of blood clotting diseases or conditions.

Modified plasmin precursors with resistance to inhibitors of plasmin

Thrombolytic composition

A plasminogen analogue activatable by thrombin to have plasmin activity which contains the cleavage site sequence (SEQ ID NO: 23): ##STR1## where Xaa at position 1 represents P4; Xaa at position 2 represents P3; Xaa at position 5 represents P1'; and Xaa at position 6 represents P2' where P3 is a basic amino acid residue, P4 is a hydrophobic amino acid residue and each of P1' and P2' is independently a non-acidic amino acid residue, said site being cleavable by thrombin between Arg and P1'.

Thrombin activatable plasminogen analogues

Inhibitor resistant serine proteases

Activatable fibrinolytic and anti-thrombotic proteins

Fibrinolytic and anti-thrombotic cleavable dimers

Human tissue plasminogen activator analogue having substitutions at

Growing community of inventors

Oxford, United Kingdom

Keith Martyn Dawson